Glucotrack to Unveil Implantable CBGM with First-in-Human Data
Glucotrack will present its implantable continuous blood glucose monitor, featuring three-year sensor longevity and positive first-in-human results, on March 17 at the LSI USA '26 Summit in Dana Point. CEO Paul V. Goode will detail the company’s U.S. clinical trial roadmap and regulatory strategy to meet unmet diabetes management needs.
1. Presentation Details
Glucotrack CEO Paul V. Goode will present at the LSI USA '26 Medtech Innovation Summit on March 17 in Dana Point, California, introducing the company’s implantable continuous blood glucose monitor and engaging investors and partners in one-on-one meetings.
2. CBGM Technology and Study Results
The device features a long-term implantable sensor with up to three-year longevity, minimal calibration requirements and no on-body wearable component, and has delivered positive first-in-human study results demonstrating accurate continuous glucose tracking.
3. Regulatory and Commercialization Strategy
During the session, Glucotrack will outline its U.S. clinical trial roadmap, FDA regulatory strategy and commercialization plans aimed at addressing significant unmet needs in diabetes management with a fully implantable CBGM system.